Pfizer and LabCentral, a Cambridge, Massachusetts-headquartered shared laboratory space for life-sciences and biotech start-ups, plan to open a new LabCentral facility, LabCentral 610, located at Pfizer’s Kendall Square Worldwide Research and Development campus in Cambridge.

The 33,000-square-foot facility is slated to open in December 2017 and will house up to six early- to mid-stage companies. The companies may be from the current LabCentral space or those interested in securing space in the bioscience Kendall Square neighborhood. A joint steering committee made up of representatives from LabCentral and Pfizer evaluate potential companies. Three local biotechs have been accepted: Affinivax, EnBiotix and Aquinnah Pharmaceuticals.

LabCentral said the LabCentral 610 site was developed in response to requests from resident start-ups outgrowing or “aging out” of its original facility who want to remain within LabCentral’s environment as they continue on in their next stage of development.

The facility contains six private lab suites and can accommodate companies ranging in size from 20 to 40 people. Common space includes: six conference rooms; four phone booth/huddle rooms; a mother’s room and nap room; a kitchen/café; and a “living room” (the corollary to the “playroom” in LabCentral’s original 700 Main Street location).

Source: LabCentral